Recent phase III trials, such as CheckMate 9DW and HIMALAYA trials, have demonstrated that combination immunotherapy with anti‐PD‐1/PD‐L1 and anti‐CTLA‐4 antibodies can improve overall survival (OS) in advanced HCC [16]. This evidence concerns the gene CD274 and hepatocellular carcinoma.